ImmunOs appoints Steve Coats as chief development officer

6 December 2021

Swiss biotech ImmunOs Therapeutics today announced that Steve Coats has been appointed as chief development officer (CDO).

Mr Coats brings more than 25 years of industry expertise with a focus on antibody drug development that includes scientific excellence coupled with executive-level success, driving strategic initiatives and innovations in drug development. Prior to joining ImmunOs, Mr Coats served as CDO at Auregen Biotherapeutics, managing and leading R&D laboratories to develop innovative cell therapies and building a strong development pipeline.

From 2005 to 2020, he held several leading positions of increasing responsibility at AstraZeneca (LSE: AZN)_and MedImmune, most recently as vice president R&D, global project leader. From 1996 to 2005, he held various research positions of increasing responsibility at Amgen (Nasdaq: AMGN), where he focused on identifying the right targets and mechanistic areas in cancer for drug development of both small molecule and biologic-based therapies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK